Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
The Shanghai Institute of Materia Medica, Chinese Academy of Sciences, manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 7 distinct examiners, indicating a broad spread of intellectual property review. This ratio of examiners to pending actions suggests that each application is receiving a unique perspective from different officials.
The portfolio spans 6 distinct art units, which is a significant level of departmental diversity for the 7 pending actions. This variety implies that the institute's research covers multiple specialized sub-fields within biotechnology. The busiest examiner, HABTE, KAHSAY, is responsible for 1 pending office action, further highlighting the lack of examiner concentration in this portfolio.
For practitioners, this distribution means that prosecution strategies must be tailored to different individual examiners. There is no primary contact at the USPTO who influences a majority of the pending applications. Success across the pending office actions will require navigating the specific preferences and standards of 6 different art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
| MCKOY, QUINCY ANDRE | 1 | 68.4% | +39.8% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724366 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014932 | PENTACYCLIC TRITERPENOID GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROZOF, TIMOTHY R | 25d overdue |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | O DELL, DAVID K | 3d overdue |
| 18839865 | SALT OF SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCYCLIC COMPOUND, CRYSTAL FORM THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF | ARCORIA, PAUL JOSEPH | — |
| 18392472 | PREPARATION OF A CLASS OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS | MCKOY, QUINCY ANDRE | — |
| 18560605 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, WILLIAM Y | — |
| 18550346 | PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR | KIM, YUNSOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014932 | PENTACYCLIC TRITERPENOID GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROZOF, TIMOTHY R | 25d overdue |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | O DELL, DAVID K | 3d overdue |
| 18392472 | PREPARATION OF A CLASS OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS | MCKOY, QUINCY ANDRE | — |
| 18560605 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, WILLIAM Y | — |
| 18550346 | PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1624 | 1 |
| 1626 | 1 |
| 1623 | 1 |
| 1641 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724366 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18839865 | SALT OF SUBSTITUTED AMINO SIX-MEMBERED NITRIC HETEROCYCLIC COMPOUND, CRYSTAL FORM THEREOF, METHOD FOR PREPARING SAME, AND USE THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18392472 | PREPARATION OF A CLASS OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS | MCKOY, QUINCY ANDRE | 1626 | §103§112 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18560605 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | LEE, WILLIAM Y | 1623 | §103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18550346 | PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR | KIM, YUNSOO | 1641 | §101§103§112DP | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | O DELL, DAVID K | 1621 | §103§112 | Final Rejection | 3d overdue | Pending | Aug 10, 2023 |
| 18014932 | PENTACYCLIC TRITERPENOID GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROZOF, TIMOTHY R | 1625 | §102§112 | Final Rejection | 25d overdue | Pending | Jan 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Institute of Materia Medica, Chinese Academy of Sciences has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Kahsay Habte has the most, with 1 of Shanghai Institute of Materia Medica, Chinese Academy of Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
